HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

Results suggest new hope for patients with refractory chronic lymphocytic leukemia Data to support BLA submission

BARCELONA, SPAIN, June 12 ---ILEXTM Oncology, Inc. (NASDAQ: ILXO) and LeukoSite, Inc. (NASDAQ: LKST) today announced final results from an international, multi-center, pivotal Phase II clinical trial of CAMPATHR for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who are refractory to fludarabine. Results of the trial were presented this weekend at the 4th Congress of the European Haematology Association (EHA) by Michael J. Keating, MB, BS, of the M.D. Anderson Cancer Center, one of the trial's principal investigators and an internationally recognized expert in CLL. The companies plan to submit a Biologics License Application (BLA) based largely on these results later this year.

"The results of this trial are encouraging," said Dr. Keating, Associate Head for Clinical Research and Professor of Medicine and internist for the Department of Leukemia at M.D. Anderson Cancer Center. "The data suggest that CAMPATH may provide an important new treatment option for fludarabine-refractory patients, a group for whom the prognosis has, to date, been extremely poor. While the treatment of patients with leukemia has relied on chemotherapeutic agents, the use of monoclonal antibodies is an innovative approach to circumventing the disease's mechanisms for resistance."

The non-comparative trial, involved 93 previously treated patients who had received prior alkylating agents and failed fludarabine therapy (median of three prior treatment regimens). For these patients, the median life expectancy is usually six to nine months.

In the trial, patients participating at the 20 clinical sites in the United States and Europe received 30 mg of CAMPATH on an outpatient basis, as an intravenous infusion, three times a week, for four to 12 weeks. The dose was gradually escalated over the first week to 30 mg, in or
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
(Date:6/30/2015)... ... June 30, 2015 , ... ... Rehab”. The video focuses on the rehab center’s patients and their experiences at ... the best quality of services available. Each patient attests to the high rating, ...
(Date:6/30/2015)... ... June 30, 2015 , ... Broadway by the Sea posted its ... and family member testimonials. Medicare rated the care center as a five-star location based ... video to give future patients a firsthand look at the facility’s satisfied residents. ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... ) currently pending in a federal multidistrict litigation now underway in the U.S. ... its next monthly Status Conference. According to the Court’s calendar, that conference has ...
(Date:6/30/2015)... ... June 30, 2015 , ... Allied ... from Allied’s Fullerton division volunteered to help provide free outpatient procedures to some ... 21, at St. Jude Medical Center. , The event was coordinated by ...
(Date:6/30/2015)... ... June 30, 2015 , ... Red Hot & Blue Restaurants, ... online poll at http://scoutology.com/novaburgerwars and was selected as “Best BBQ” in a ... 2015. , Red Hot & Blue President Randy McCann said, “Everyone knows Red Hot ...
Breaking Medicine News(10 mins):Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 3Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 2Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 3
(Date:6/30/2015)... BERKELEY, Calif. and COPENHAGEN, ... CMC Biologics, Inc. , a global leader in clinical ... proteins, announced today that, as part of its global ... of its North American manufacturing facility in ... single-use Bioreactor 6Pack™ facility.  The Bioreactor 6Pack™ configuration consists ...
(Date:6/30/2015)... 2015 Legal-Bay LLC, the Lawsuit Settlement Funding ... the multidistrict litigation (MDL) over the Zimmer NexGen Knee ... th , 2015. There are currently more than a ... before a federal judge in Illinois ... will begin in October of this year. Zimmer Inc. ...
(Date:6/29/2015)... -- Mordor Intelligence presents their Global Pharmaceutical ... Glass, Paper, Metal) - ByType of Packaging (Ampules, Blister Packs, ... Sachets) - By Geographical Region ( North America ... , Latin America , ... - discussing Industry Value Chain Analysis, Porter,s 5 Force Analysis, ...
Breaking Medicine Technology:CMC Biologics Expands GMP Manufacturing Capacity in the United States 2CMC Biologics Expands GMP Manufacturing Capacity in the United States 3Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 2Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 3Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 2Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 3
Cached News: